International Journal of
Science Inventions Today
www.ijsit.com
ISSN 2319-5436
Review Article

ADVANCES IN DIAGNOSIS AND TREATMENT OF ATOPIC DERMATITIS

Mursal Abdullahi Nur[1], Lagan Kumar[1], Menene Nkonika Dieu-Merci[2], Ayan Ibrahim Ali[3] and Deng Danqi[1*]

[1*]Dermatology Department, The Second Affiliated Hospital of Kunming Medical University

[1]Gastroenterology Department, The Second Affiliated Hospital of Kunming Medical University

[2]Medical Imaging Department, The First Affiliated Hospital of Kunming Medical University

[3]Basic Emergency Obstetric and Newborn Care Department, Somali Red Crescent Society (SRCS) Halgan Health Center

ABSTRACT

Atopic Dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly affects patients' quality of life, with a growing prevalence worldwide, particularly in children. While the pathophysiology of AD remains complex, recent research has deepened our understanding of its underlying mechanisms, including immune dysregulation, skin barrier dysfunction, and genetic predispositions. Advances in diagnostic strategies, such as the development of novel biomarkers and imaging techniques, have enabled early and accurate diagnosis, paving the way for targeted treatments. The management of AD has seen a paradigm shift with the advent of biologic therapies and other novel treatments, which offer more effective and personalized approaches with fewer side effects compared to conventional treatments. Additionally, research into the role of the skin microbiome and its impact on disease progression has opened new avenues for therapeutic intervention. This review summarizes the most recent developments in the diagnosis and treatment of AD, examining both established and emerging therapeutic strategies and their impact on patient outcomes.

Keywords: Atopic Dermatitis, Diagnosis, Biologic Therapies, Skin Microbiome, Targeted Therapy

INTRODUCTION

Atopic Dermatitis (AD), also known as eczema, is a chronic inflammatory skin condition characterized by pruritus, erythema, and scaling. It commonly manifests in childhood and can persist into adulthood, affecting a significant portion of the global population. According to recent epidemiological studies, the global prevalence of AD ranges from 15% to 30% in children and 2% to 10% in adults. The condition not only causes physical discomfort but also leads to psychological distress due to its impact on appearance and quality of life. Many patients with AD experience sleep disturbances, anxiety, and depression, further exacerbating the disease burden [1,2]. Given the rising prevalence of AD, understanding its underlying pathophysiology is crucial for improving diagnosis and treatment strategies. The disease is multifactorial, involving a complex interplay of genetic, immunologic, and environmental factors.

Recent advancements in both diagnostic tools and treatment options for AD have improved patient care. Emerging diagnostic techniques, such as biomarker-based assessments and imaging technologies, provide a more precise and early diagnosis [3]. In parallel, novel therapeutic strategies, including biologics and small-molecule inhibitors, have expanded treatment options, offering more targeted and personalized approaches [4]. This review explores these innovations, particularly those that enhance early diagnosis and more effective treatment outcomes, thereby improving patient quality of life.

ADVANCES IN DIAGNOSIS OF ATOPIC DERMATITIS

Atopic dermatitis (AD) remains a clinically challenging condition to diagnose due to its heterogeneous presentation across different age groups and populations. Over the years, significant advancements have been made in refining diagnostic approaches, incorporating both traditional clinical assessments and emerging molecular, imaging, and biomarker-based techniques. These improvements have contributed to a more accurate and personalized approach to diagnosing AD.

Clinical diagnosis:

The diagnosis of AD is primarily clinical, relying on a thorough patient history and physical examination. Characteristic features include chronic or relapsing pruritic eczematous lesions that manifest on specific body areas depending on age. In infants, lesions commonly appear on the face and extensor surfaces, whereas in adults, they often affect flexural areas, hands, and even the eyelids. Historically, the Hanifin and Rajka criteria have been the gold standard for AD diagnosis, consisting of both major and minor criteria encompassing clinical features such as pruritus, typical morphology, chronicity, and family history (Hanifin & Rajka, 1980). However, these criteria have limitations, particularly in adult patients, where atypical presentations, including nummular eczema-like or prurigo-like lesions, can complicate diagnosis. Recent research has expanded on these criteria by recognizing different phenotypes of AD, including early-onset and late-onset forms, as well as variations influenced by comorbid conditions such as asthma and allergic rhinitis [5,6]. Understanding these variations can enhance diagnostic accuracy and support a more individualized

treatment approach.

Molecular and biomarker-based approaches:

Molecular and biomarker-based diagnostics have emerged as valuable tools in distinguishing AD from other inflammatory skin disorders. Elevated serum levels of immunoglobulin E (IgE) and eosinophil cationic protein (ECP) are often associated with AD, particularly in patients with severe or persistent disease. Other promising biomarkers include thymic stromal lymphopoietin (TSLP), periostin, and interleukin (IL)-13, which play key roles in the immune dysregulation underlying AD [7]. Genetic studies have further improved our understanding of AD susceptibility. Mutations in the filaggrin (FLG) gene, which is critical for maintaining the skin barrier, are strongly associated with an increased risk of AD, particularly in individuals with early-onset or persistent disease. Genetic profiling may aid in identifying high-risk individuals and could facilitate early intervention strategies. Beyond diagnosis, biomarker analysis can also assist in monitoring disease activity and treatment response. These biomarkers are being utilized in clinical settings to aid in diagnosis, prognosis, and monitoring treatment response. For instance, TARC (thymus and activation-regulated chemokine) levels have been shown to correlate with disease severity and can be used as an indicator of flare-ups. Commercially available assays for IgE, periostin, and TARC are increasingly being integrated into clinical practice, allowing for more personalized treatment adjustments [8].

Imaging techniques:

Non-invasive imaging technologies have provided new avenues for diagnosing and monitoring AD. Reflectance confocal microscopy (RCM) allows for real-time, high-resolution imaging of the skin at a cellular level, enabling physicians to assess epidermal changes and inflammatory activity without the need for invasive biopsies [9]. This technique has proven particularly useful in distinguishing AD from other eczematous conditions. While RCM is highly effective in identifying microscopic changes in AD, optical coherence tomography (OCT) and high-frequency ultrasound (HFUS) offer advantages in assessing deeper skin layers [10,11].

Another innovative approach is skin surface microtopography, which evaluates skin barrier integrity by analyzing the structural abnormalities characteristic of AD. This technique provides objective measurements of barrier dysfunction, further aiding in both diagnosis and treatment planning.

Differential diagnosis:

Distinguishing AD from other skin disorders is key to ensuring the right treatment. Conditions like psoriasis, seborrheic dermatitis, allergic contact dermatitis, and cutaneous T-cell lymphoma can all look similar, with features like redness and scaling, but they have different causes and require different treatments. In more complicated cases where the symptoms alone aren't enough, diagnostic tools like patch testing, histopathology, and newer methods like transcriptomic analysis become really important in making an accurate diagnosis and avoiding misclassification [12].

Diagnostic Approach	Key features	Advantages	Limitations
Clinical Diagnosis	Hanifin and Rajka criteria, patient history, physical examination	Non-invasive, widely available	Limited by atypical presentations in adults
Molecular Biomarkers	Serum IgE, TSLP, periostin, IL-13, TARC	Objective, aids in personalized treatment	Costly, variability in results across populations
Genetic Profiling	FLG gene mutations, genetic susceptibility markers	Identifies high-risk individuals, enables early intervention	Limited accessibility, not yet routine in clinical practice
Imaging Techniques	Reflectance confocal microscopy (RCM), optical coherence tomography (OCT), HFUS	Non-invasive, provides real-time imaging of skin layers	Expensive, requires specialized equipment and expertise
Skin Surface Microtopography	Analyzes skin barrier integrity, structural abnormalities	Objective measurement of barrier dysfunction	Limited availability, not widely adopted

Table 1: Summarizing the key diagnostic approaches for AD, highlighting their advantages and limitations.

ADVANCES IN TREATMENT OF ATOPIC DERMATITIS

Topical treatments:

Topical corticosteroids (TCS) have long been the mainstay of AD treatment due to their potent anti-inflammatory effects. They are classified based on potency, ranging from mild (e.g., hydrocortisone) to very potent (e.g., clobetasol propionate), and are used to manage acute flares of AD. However, prolonged use of TCS can lead to adverse effects such as skin atrophy, striae, and tachyphylaxis. To mitigate these effects, newer, less-potent corticosteroids and steroid-sparing agents have been developed. For example, topical calcineurin inhibitors (TCIs), such as tacrolimus and pimecrolimus, provide an effective alternative to TCS, particularly for sensitive areas like the face and eyelids. TCIs inhibit T-cell activation and cytokine release, reducing inflammation without causing skin thinning. Recent studies have reinforced their long-term safety and efficacy in both children and adults.

Phosphodiesterase-4 (PDE4) inhibitors, such as crisaborole, have emerged as a novel topical treatment for mild to moderate AD. PDE4 inhibition reduces inflammation by modulating cyclic AMP levels within immune cells. Clinical trials have demonstrated that crisaborole is well tolerated and effective in

reducing pruritus and lesion severity in AD patients [13].

In addition, barrier repair therapy has gained prominence as a cornerstone of AD management. Emollients containing ceramides, cholesterol, and free fatty acids help restore the defective skin barrier in AD patients. Novel formulations incorporating natural moisturizers like filaggrin-derived peptides and sphingolipids have shown promise in reducing flare frequency and improving skin hydration.

Systemic therapies:

While topical therapies remain the first-line treatment, patients with moderate to severe AD often require systemic therapies to achieve disease control. Traditional immunosuppressive agents, such as cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil, have been used for decades to control inflammation. However, these medications are associated with notable side effects, including nephrotoxicity, hepatotoxicity, and bone marrow suppression, requiring close monitoring [14,15]. In recent years, biologic therapies have transformed the treatment landscape for AD by targeting specific immune pathways. Dupilumab, a monoclonal antibody that inhibits the IL-4 and IL-13 signaling pathways, was the first biologic approved for moderate to severe AD. Clinical trials have consistently demonstrated its efficacy in reducing disease severity, improving quality of life, and reducing the need for systemic steroids [16]. Newer biologics targeting specific cytokines involved in the Th2 inflammatory pathway, such as IL-13 inhibitors, have shown promising results. Tralokinumab, for example, has demonstrated significant efficacy in reducing AD symptoms and has a favorable long-term safety profile [17]. Similarly, lebrikizumab has shown efficacy in phase 3 trials, offering a potential alternative for patients who do not respond to dupilumab [18].

Janus kinase (JAK) inhibitors:

Janus kinase (JAK) inhibitors represent a significant advancement in the treatment and potentially the diagnosis of atopic dermatitis (AD). These targeted therapies work by blocking the activity of JAK enzymes, which are involved in the signaling pathways of various cytokines that contribute to the inflammatory process in AD. By inhibiting JAK activity, these medications can effectively reduce inflammation, improve skin barrier function, and manage the pruritus associated with AD [19]. The use of JAK inhibitors has shown promise in clinical trials, particularly for patients with moderate to severe AD who have not responded well to conventional treatments such as topical corticosteroids or calcineurin inhibitors. Drugs like upadacitinib and abrocitinib, represent a significant advancement in AD treatment by targeting immune cell activation pathways. These oral treatments provide rapid and sustained improvement in key AD symptoms, offering an alternative to injectable biologics. Clinical trials show their efficacy in reducing symptoms, often matching biologics' results [20,21].

However, JAK inhibitors may not be suitable for everyone, as they carry risks such as increased susceptibility to infections (herpes zoster, tuberculosis, hepatitis B, and C), thromboembolic events (deep vein thrombosis, pulmonary embolism). They may not be suitable for individuals with a history of cardiovascular disease, liver dysfunction, or malignancies. Given these concerns, before initiating treatment with JAK inhibitors, a thorough medical assessment is necessary, including screening for pre-existing

conditions and baseline lab tests [22,23].

Phototherapy:

Phototherapy, particularly narrowband ultraviolet B (NB-UVB), remains a well-established treatment for moderate to severe atopic dermatitis (AD). It helps reduce inflammation by modulating immune responses and promoting skin barrier repair. It has been shown that NB-UVB can significantly improve symptoms and reduce the need for systemic therapies, making it a valuable option for patients who do not respond adequately to topical treatments. However, phototherapy requires multiple sessions per week over several months, which can be inconvenient and costly for some patients. Potential side effects include skin dryness, erythema, and an increased long-term risk of photoaging and skin cancer with prolonged use [24]. To enhance convenience and precision, excimer laser therapy has been explored as a more targeted alternative for localized AD lesions. This therapy delivers concentrated UVB light directly to affected areas, minimizing exposure to healthy skin, while promising, its availability and cost remain barriers to widespread use [25].

Emerging and experimental therapies:

The role of the skin microbiome in atopic dermatitis (AD) has gained increasing attention, as microbial imbalances, particularly *Staphylococcus aureus* colonization can trigger inflammation and worsen skin barrier dysfunction. Novel microbiome-based therapies, including topical probiotics, bacterial lysates, and phage therapy, are being explored to restore microbial diversity and reduce disease severity [26]. Beyond microbiome-targeted interventions, new therapies aim to modulate key inflammatory and environmental pathways involved in AD. Aryl hydrocarbon receptor (AhR) modulators, such as tapinarof, have shown promise in reducing oxidative stress and restoring immune balance, potentially offering an effective non-steroidal topical treatment [27]. These emerging therapies may complement existing treatments, paving the way for more personalized and sustainable disease management.



Figure 1: Overview of Treatment Modalities for Atopic Dermatitis (AD)

This figure outlines various treatments for Atopic Dermatitis (AD), categorizing them by their mechanisms of action and therapeutic effects. Key treatments include: (1) Topical Treatments: TCI (Topical Calcineurin Inhibitors), & TCS (Topical Corticosteroids): inhibit T-cell activation and reduce inflammation; PDE-4 Inhibitors: Suppress inflammatory pathways by inhibiting phosphodiesterase-4, leading to reduced cytokine production; JAK Inhibitors: Block JAK-STAT signaling, reduce cytokine-driven inflammation, and provide fast symptom relief; (2) Systemic Treatments: Azathioprine & Methotrexate: suppress immune response and reduce inflammation; Tralokinumab: Target IL-13 signaling, reduces inflammation, and improves skin barrier; Dupilumab: inhibit interleukin-4 (IL-4) receptor alpha and interleukin-13 (IL-13) signaling; Cyclosporine: inhibit T-cell activation and reduce inflammation; Each treatment modality offers unique mechanisms to manage AD symptoms and improve skin health.

DISCUSSION

The advancements in the diagnosis and treatment of atopic dermatitis (AD) have significantly improved patient outcomes, yet challenges remain. The integration of molecular, biomarker-based, and imaging techniques has enhanced diagnostic accuracy, allowing for earlier and more personalized interventions. However, the heterogeneity of AD presentations across different age groups and populations continues to pose diagnostic challenges. Future research should focus on refining diagnostic criteria and developing non-invasive tools that can be easily integrated into clinical practice.

On the treatment front, the advent of biologic therapies and JAK inhibitors has revolutionized AD

management, offering targeted and effective options for patients with moderate to severe disease. These therapies have shown remarkable efficacy in reducing symptoms and improving quality of life, but their high cost and accessibility remain significant barriers, particularly in low-income settings [28]. Additionally, the long-term safety profiles of these novel treatments require further investigation, especially concerning the risk of infections and thromboembolic events associated with JAK inhibitors [29]. The role of the skin microbiome in AD pathogenesis has opened new avenues for therapeutic intervention. Microbiome-based therapies, such as topical probiotics and phage therapy, hold promise for restoring microbial balance and reducing disease severity [30]. However, more research is needed to fully understand the complex interactions between the microbiome and the immune system in AD.

Personalized medicine is emerging as a key strategy in AD management. Advances in omics technologies (genomics, proteomics, metabolomics) and machine learning algorithms are enabling the development of tailored treatment plans based on individual patient profiles. Biomarker-driven therapy selection, pharmacogenomics, and predictive modeling are being explored to optimize treatment efficacy while minimizing adverse effects [31,32].

Future research should focus on integrating AI-driven diagnostics and machine learning algorithms to predict disease progression and optimize treatment plans. Additionally, the development of cost-effective therapies and global health initiatives will be crucial in improving access to advanced diagnostics and treatments, particularly in low-resource settings. Collaborative efforts between researchers, clinicians, and policymakers are essential to ensure that these innovations are accessible to all patients, regardless of socioeconomic status.

PATIENT-CENTERED CONSIDERATIONS

Personalized medicine:

The complexity of AD requires a personalized treatment approach. Factors such as age, disease severity, genetic predispositions, comorbid conditions, and patient preferences must be considered when devising a treatment plan. Biomarkers can play a crucial role in this, helping to tailor therapies based on the specific pathophysiological features of the disease in individual patients [33].

Quality of life:

AD has a profound impact on quality of life, causing physical discomfort and psychological distress. The recent advancements in treatment have allowed for better disease control, leading to significant improvements in patients' quality of life. Reducing the frequency and severity of flare-ups, managing itch, and minimizing side effects from treatment are key aspects of patient-centered care in AD [34].

CHALLENGES AND FUTURE DIRECTIONS

Despite significant advancements in the diagnosis and treatment of AD, several challenges remain. Current treatments do not provide a cure, and there is a need for long-term solutions that address both

immune dysregulation and skin barrier dysfunction. Additionally, while biologics and other novel therapies show promise, their high cost and accessibility remain barriers for many patients, particularly in low-income settings.

Future research should focus on better understanding the genetic and environmental factors contributing to AD, as well as identifying novel therapeutic targets. The role of the microbiome and the development of non-invasive diagnostic tools are also areas of ongoing exploration that may transform AD management in the coming years.

CONCLUSION

Advances in the diagnosis and treatment of atopic dermatitis have significantly improved patient outcomes, particularly with the introduction of biologic therapies and personalized treatment strategies. The integration of molecular, biomarker-based, and imaging techniques has enhanced diagnostic accuracy, allowing for earlier and more personalized interventions. Similarly, the advent of biologics and JAK inhibitors has revolutionized AD management, offering targeted and effective options for patients with moderate to severe disease.

However, challenges remain, including diagnostic heterogeneity, treatment accessibility, and long-term safety concerns. The high cost of biologics and JAK inhibitors limits their accessibility, particularly in low- and middle-income countries. Additionally, the long-term safety of newer therapies, such as JAK inhibitors, remains uncertain, necessitating further research.

Future research should focus on integrating AI-driven diagnostics, improving global access to treatments, and exploring novel therapeutic targets, such as IL-22/IL-33 blockers and microbiome-based therapies. By continuing to build on our understanding of the disease's complex mechanisms, we can hope to provide more targeted care for patients affected by this chronic condition.

REFERENCES

1. Lobefaro F, Gualdi G, Di Nuzzo S, Amerio P. Atopic Dermatitis: Clinical Aspects and Unmet Needs. Biomedicines. 2022 Nov 14;10(11):2927. doi: 10.3390/biomedicines10112927
2. Courtney A, Su JC. The Psychology of Atopic Dermatitis. J Clin Med. 2024 Mar 11;13(6):1602. doi: 10.3390/jcm13061602.
3. Meledathu S, Naidu MP, Brunner PM. Update on atopic dermatitis. J Allergy Clin Immunol. 2025 Jan 22:S0091-6749(25)00064-8. doi: 10.1016/j.jaci.2025.01.013.
4. Plant A, Ardern-Jones MR. Advances in atopic dermatitis. Clin Med (Lond). 2021 May;21(3):177-181. doi: 10.7861/clinmed.2021-0280.
5. Thyssen JP, Halling AS, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JI. Comorbidities of atopic dermatitis-what does the evidence say? J Allergy Clin Immunol. 2023 May;151(5):1155-1162. doi:

10.1016/j.jaci.2022.12.002.

6. Jeskey J, Kurien C, Blunk H, Sehmi K, Areti S, Nguyen D, Hostoffer R. Atopic Dermatitis: A Review of Diagnosis and Treatment. J Pediatr Pharmacol Ther. 2024 Dec;29(6):587-603. doi: 10.5863/1551-6776-29.6.587.
7. Tan IJ, Podwojniak A, Parikh A, Cohen BA. Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies. Curr Issues Mol Biol. 2024 Mar 30;46(4):2975-2990. doi: 10.3390/cimb46040186.
8. Mastraftsi S, Vrioni G, Bakakis M, Nicolaidou E, Rigopoulos D, Stratigos AJ, Gregoriou S. Atopic Dermatitis: Striving for Reliable Biomarkers. J Clin Med. 2022 Aug 9;11(16):4639. doi: 10.3390/jcm11164639.
9. Bratu D, Boda D, Caruntu C. Reflectance Confocal Microscopy in Monitoring Atopic Dermatitis Treated with Topical Calcineurin Inhibitors. Healthcare (Basel). 2023 Jan 4;11(2):152. doi: 10.3390/healthcare11020152.
10. Ha-Wissel L, Yasak H, Huber R, Zillikens D, Ludwig RJ, Thaçi D, Hundt JE. Case report: Optical coherence tomography for monitoring biologic therapy in psoriasis and atopic dermatitis. Front Med (Lausanne). 2022 Sep 27;9:995883. doi: 10.3389/fmed.2022.995883.
11. Sabău M, Boca AN, Ilies RF, Tătaru A. Potential of high-frequency ultrasonography in the management of atopic dermatitis. Exp Ther Med. 2019 Feb;17(2):1073-1077. doi: 10.3892/etm.2018.6984.
12. Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, Szymczak S, Swindell WR, Sarkar MK, Raja K, Shao S, Patrick M, Gao Y, Uppala R, Perez White BE, Getsios S, Harms PW, Maverakis E, Elder JT, Franke A, Gudjonsson JE, Weidinger S. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. J Invest Dermatol. 2019 Jul;139(7):1480-1489. doi: 10.1016/j.jid.2018.12.018.
13. Li H, Zuo J, Tang W. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol. 2018 Oct 17;9:1048. doi: 10.3389/fphar.2018.01048.
14. Bußmann C, Novak N. Systemic therapy of atopic dermatitis. Allergol Select. 2017 Aug 4;1(1):1-8. doi: 10.5414/ALX01285E.
15. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014 Feb;133(2):429-38. doi: 10.1016/j.jaci.2013.07.049.
16. Wu S, Wang H. Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized controlled trials. Postepy Dermatol Alergol. 2022 Jun;39(3):601-610. doi: 10.5114/ada.2022.117740.
17. Simpson EL, Pink AE, Blauvelt A, Gooderham M, Armstrong AW, Worm M, Katoh N, Peris K, Puig L, Barbarot S, Mark T, Steffensen LA, Tindberg AM, Wollenberg A. Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials. Am J Clin Dermatol. 2023 Nov;24(6):939-952. doi: 10.1007/s40257-023-00806-3.

18. Guttman-Yassky E, Rosmarin D, de Bruin-Weller M, Weidinger S, Bieber T, Hong HC, Elmaraghy H, Atwater AR, Pierce E, Xu C, Agell H, Garcia Gil E, Simpson E. The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials. J Am Acad Dermatol. 2024 Dec 27:S0190-9622(24)03414-5. doi: 10.1016/j.jaad.2024.12.026.
19. Lee KP, Plante J, Korte JE, Elston DM. Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta-analysis. Skin Health Dis. 2022 May 23;3(1):e133. doi: 10.1002/ski2.133.
20. Gooderham MJ, de Bruin-Weller M, Weidinger S, Cork MJ, Eichenfield LF, Simpson EL, Tsianakas A, Kerkmann U, Feeney C, Romero W. Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations. Dermatol Ther (Heidelb). 2024 Aug;14(8):2285-2296. doi: 10.1007/s13555-024-01200-5.
21. Simpson EL, Prajapati VH, Leshem YA, Chovatiya R, de Bruin-Weller MS, Ständer S, Pink AE, Calimlim BM, Lee WJ, Teixeira H, Ladizinski B, Hu X, Yang Y, Liu Y, Liu M, Grada A, Platt AM, Silverberg JI. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2). Dermatol Ther (Heidelb). 2024 May;14(5):1127-1144. doi: 10.1007/s13555-024-01157-5.
22. Kotyla PJ, Engelmann M, Giemza-Stokłosa J, Wnuk B, Islam MA. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? Int J Mol Sci. 2021 Feb 28;22(5):2449. doi: 10.3390/ijms22052449.
23. Kirchhof MG, Prajapati VH, Gooderham M, Hong CH, Lynde CW, Maari C, Turchin I, Papp KA. Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors. Dermatol Ther (Heidelb). 2024 Sep;14(9):2653-2668. doi: 10.1007/s13555-024-01243-8.
24. Lee RRS, Cai SC, Wong Y, Yew YW, Oon HH, Chong WS, Tey HL, Tan ES. Efficacy and safety of narrowband ultraviolet B versus combined ultraviolet A/narrowband ultraviolet B phototherapy in the treatment of chronic atopic dermatitis: A randomised double-blind study. Exp Dermatol. 2024 Jan;33(1):e15012. doi: 10.1111/exd.15012.
25. Baltás E, Csoma Z, Bodai L, Ignácz F, Dobozy A, Kemény L. Treatment of atopic dermatitis with the xenon chloride excimer laser. J Eur Acad Dermatol Venereol. 2006 Jul;20(6):657-60. doi: 10.1111/j.1468-3083.2006.01495.x.
26. Huang C, Zhuo F, Guo Y, Wang S, Zhang K, Li X, Dai W, Dou X, Yu B. Skin microbiota: pathogenic roles and implications in atopic dermatitis. Front Cell Infect Microbiol. 2025 Jan 14;14:1518811. doi: 10.3389/fcimb.2024.1518811.
27. Silverberg JI, Boguniewicz M, Quintana FJ, Clark RA, Gross L, Hirano I, Tallman AM, Brown PM, Fredericks D, Rubenstein DS, McHale KA. Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review. J Allergy Clin Immunol. 2024 Jul;154(1):1-10. doi: 10.1016/j.jaci.2023.12.013.
28. Kim RW, Lam M, Abuabara K, Simpson EL, Drucker AM. Targeted Systemic Therapies for Adults with

Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors. Am J Clin Dermatol. 2024 Mar;25(2):179-193. doi: 10.1007/s40257-023-00837-w.

29. Manzar D, Nair N, Suntres E, Rodrigues M, Alghanemi L, Abu-Hilal M. Systematic review and network meta-analysis of the risk of malignancy with biologic therapies and selective Janus kinase-1 inhibitors in atopic dermatitis. Postepy Dermatol Alergol. 2024 Jun;41(3):270-275. doi: 10.5114/ada.2024.141125.
30. Mandlik DS, Mandlik SK. Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies. Immunopharmacol Immunotoxicol. 2021 Apr;43(2):105-125. doi: 10.1080/08923973.2021.1889583.
31. Nakajima S, Nakamizo S, Nomura T, Ishida Y, Sawada Y, Kabashima K. Integrating multi-omics approaches in deciphering atopic dermatitis pathogenesis and future therapeutic directions. Allergy. 2024 Sep;79(9):2366-2379. doi: 10.1111/all.16183.
32. Cabanillas B, Brehler AC, Novak N. Atopic dermatitis phenotypes and the need for personalized medicine. Curr Opin Allergy Clin Immunol. 2017 Aug;17(4):309-315. doi: 10.1097/ACI.0000000000000376.
33. Bakker D, de Bruin-Weller M, Drylewicz J, van Wijk F, Thijs J. Biomarkers in atopic dermatitis. J Allergy Clin Immunol. 2023 May;151(5):1163-1168. doi: 10.1016/j.jaci.2023.01.019.
34. Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020 Apr;59(4):e75-e91. doi: 10.1111/ijd.14763.